- Approval Id
- 88b33f1b1631c535
- Drug Name
- LUMIGAN (BIMATOPROST OPHTHALMIC SOLUTION) 0.01%
- Product Name
- LUMIGAN (BIMATOPROST OPHTHALMIC SOLUTION) 0.01%
- Approval Number
- SIN14365P
- Approval Date
- 2013-06-13
- Registrant
- ABBVIE PTE. LTD.
- Licence Holder
- ABBVIE PTE. LTD.
- Drug Type
- Therapeutic
- Forensic Classification
- PRESCRIPTION ONLY MEDICINES
- Dosage Form
- SOLUTION, STERILE
- Dosage
- <p><strong>2 DOSAGE AND ADMINISTRATION</strong></p>
<p>The recommended dosage is one drop in the affected eye(s) once daily in the evening. <strong>LUMIGAN</strong>® 0.01% (bimatoprost ophthalmic solution) should not be administered more than once daily since it has been shown that more frequent administration of prostaglandin analogs may decrease the intraocular pressure lowering effect.</p>
<p>Reduction of the intraocular pressure starts approximately 4 hours after the first administration with maximum effect reached within approximately 8 to 12 hours.</p>
<p><strong>LUMIGAN</strong>® 0.01% may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.</p>
- Route Of Administration
- OPHTHALMIC
- Indication Info
- <p><strong>1 INDICATIONS AND USAGE</strong></p>
<p><strong>LUMIGAN</strong>® 0.01% (bimatoprost ophthalmic solution) is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.</p>
- Contraindications
- <p><strong>4 CONTRAINDICATIONS</strong></p>
<p><strong>LUMIGAN</strong>® 0.01% is contraindicated in patients with clinically significant hypersensitivity to bimatoprost or to any of the excipients.</p>
- Atc Code
- S01EE03
- Atc Item Name
- bimatoprost
- Pharma Manufacturer Name
- ABBVIE PTE. LTD.
- Company Detail Path
- /organization/abbvie-pte-ltd
